The Baker Bros. buy signals confidence from the largest holder, but the CEO/CFO/CMO/CAO selling—especially the CEO's $510K sale on the offering pricing date—is a cautionary signal. Monitor for additional insider sales in the next 30 days; if C-suite selling continues above $1M total, it would suggest insiders are taking advantage of the post-approval pop. The TUDRIQEV launch and IGNYTE-3 confirmatory trial data are the next catalysts.
Price Chart
Executive Summary
Replimune insiders show a mixed cluster: Baker Bros. (10% owner) bought $1.52M in the public offering at $12.06, while the CEO, CFO, CMO, and CAO collectively sold $889K in open-market sales. The CEO/CMO/CAO sales on 8/10 coincided with the $150M dilutive offering priced at $12.06, and the CFO's sale on 8/17 followed the stock's rise to $14.28 after the FDA approval of TUDRIQEV. The Baker Bros. buy is a strong vote of confidence from the largest holder, but the C-suite selling—especially the CEO's $510K sale—creates a bearish signal that partially offsets the bullish approval catalyst.
Key Financial Metrics
Key Facts
- Baker Bros. Advisors LP (10% owner) bought 126,400 shares at $12.06 for $1.52M on 8/11, participating in the $150M public offering.
- CEO Sushil Patel sold 39,300 shares at $12.97 for $510K on 8/10, the same day the $150M offering was priced.
- CFO Emily Luisa Hill sold 9,256 shares at $14.28 for $132K on 8/17, after the stock rose post-FDA approval.
- CMO Konstantinos Xynos sold 11,400 shares at $12.97 for $148K on 8/10.
- CAO Andrew Schwendenman sold 7,600 shares at $12.97 for $99K on 8/10.
- Total insider open-market sales: $889K; total insider buy: $1.52M; net cluster value: +$631K (buy-side).
- The $150M offering (424B5) closed 9 days prior, diluting existing shareholders by ~13%.
- FDA accelerated approval of TUDRIQEV (RP1) was granted on 8/6/2026, transforming Replimune into a commercial-stage biotech.
Financial Impact
Insider cluster net buy of $631K, but C-suite sales of $889K (0.06% of $1.5B market cap) are modest in size. The $150M offering represents ~13% dilution.
Risk Factors
- C-suite selling (CEO, CFO, CMO, CAO) within days of FDA approval and a dilutive offering suggests insiders may view the current valuation as a selling opportunity.
- The $150M offering diluted existing shareholders by ~13%, and the company has never generated product revenue.
- TUDRIQEV's accelerated approval requires confirmatory trial (IGNYTE-3) data; failure could lead to withdrawal.
- Historical calibration shows REPL insider cluster reports have a 0% win rate at T+20 (n=3 settled), suggesting the market may not follow these signals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-REPL-1787180496366 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 5w ago | Press Release | $14.71 $13.07 | ▲ +11.15% | ▲ +11.16% | $13.04 (+11.35%) |
Aug 19, 2026 6w ago | Insider Cluster | $14.05 $13.07 | ▼ −6.98% | ▼ −6.98% | $13.04 (−7.19%) |
Aug 14, 2026 7w ago | 8-K | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 14, 2026 7w ago | Press Release | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 10, 2026 7w ago | Press Release | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 8-K | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 424B5 | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 7, 2026 8w ago | 8-K | $12.06 $15.04 | ▲ +24.71% | ▲ +25.11% | $13.04 (+8.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access